HomeCompareENZ vs PLD

ENZ vs PLD: Dividend Comparison 2026

ENZ yields 127.47% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENZ wins by $5.38M in total portfolio value
10 years
ENZ
ENZ
● Live price
127.47%
Share price
$0.31
Annual div
$0.40
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11.29M
Annual income
$4,437,918.34
Full ENZ calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — ENZ vs PLD

📍 ENZ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENZPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENZ + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENZ pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENZ
Annual income on $10K today (after 15% tax)
$10,834.93/yr
After 10yr DRIP, annual income (after tax)
$3,772,230.59/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $265,885.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENZ + PLD for your $10,000?

ENZ: 50%PLD: 50%
100% PLD50/50100% ENZ
Portfolio after 10yr
$8.60M
Annual income
$4,594,321.76/yr
Blended yield
53.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ENZ
No analyst data
Altman Z
-5.6
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENZ buys
0
PLD buys
0
No recent congressional trades found for ENZ or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENZPLD
Forward yield127.47%3.10%
Annual dividend / share$0.40$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$11.29M$5.91M
Annual income after 10y$4,437,918.34$4,750,725.19
Total dividends collected$10.31M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ENZ vs PLD ($10,000, DRIP)

YearENZ PortfolioENZ Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$23,447$12,746.97$11,241$540.96+$12.2KENZ
2$53,021$27,932.52$13,019$991.13+$40.0KENZ
3$115,764$59,031.74$15,801$1,870.97+$100.0KENZ
4$244,324$120,456.19$20,609$3,701.21+$223.7KENZ
5$499,021$237,595.07$29,919$7,867.97+$469.1KENZ
6$987,484$453,531.34$50,631$18,617.74+$936.9KENZ
7$1,895,362$838,753.88$105,528$51,352.20+$1.79MENZ
8$3,532,609$1,504,571.30$287,364$174,449.42+$3.25MENZ
9$6,400,682$2,620,790.80$1,081,760$774,280.77+$5.32MENZ
10$11,286,648$4,437,918.34$5,908,209$4,750,725.19+$5.38MENZ

ENZ vs PLD: Complete Analysis 2026

ENZStock

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

Full ENZ Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ENZ vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENZ vs SCHDENZ vs JEPIENZ vs OENZ vs KOENZ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.